We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Automated Periostin Immunoassay Developed

By LabMedica International staff writers
Posted on 11 Jan 2017
Print article
Image: The ARCHITECT i1000SR immunoassay analyzer (Photo courtesy of Abbott).
Image: The ARCHITECT i1000SR immunoassay analyzer (Photo courtesy of Abbott).
Periostin is being investigated as a potential biomarker for T-helper-2 (Th2)-driven asthma or eosinophilic inflammation and may help to identify patients more likely to benefit from interleukin-13-targeted treatments.

The use of serum interleukin-13 (IL-13) itself as a biomarker is challenging because it is expressed locally in inflamed tissue, resulting in very low concentrations in serum and concentrations of serum IL-13 appear to be similar between healthy controls and subjects with asthma.

Scientists at Abbott Laboratories (Abbott Park, IL, USA) and their colleagues assessed the company’s ARCHITECT Periostin Immunoassay performance in terms of precision, sensitivity, linearity, interference from classical immunoassay interferents and representatives of common asthma medications, specimen handling, and isoform reactivity. The assay has been developed for use with the ARCHITECT Immunoassay i System.

Samples from subjects with idiopathic pulmonary fibrosis, subjects with asthma used in periostin concentration assessments, and normal samples from healthy volunteers were obtained. The test is a monoclonal antibody (mAb) sandwich two-step immunoassay for the quantitative determination of periostin in human serum using chemiluminescent magnetic immunoassay technology. Periostin, the analyte, is captured by microparticles coated with an anti-periostin mAb and subsequently detected with a second anti-periostin mAb conjugated with Acridinium.

The team reported that the percentage of coefficient of variation (CVs) for five-day total precision, assessed using two instruments was less than 6% across two controls and one serum-based panel. Limit of quantitation was 4 ng/mL, using dilution adjusted concentration, suiting the needs for the application. Dilution analysis yielded linear results and no endogenous sample or drug interferences were observed. All known periostin isoforms expressed in the mature human lung were detected by the assay.

The authors concluded that their analysis of periostin concentration in serum samples appeared to show slightly elevated mean periostin concentrations in samples from subjects with uncontrolled asthma compared with apparently healthy volunteers. This is consistent with reports of elevated serum periostin concentration in subjects with asthma, particularly those with Th2-driven asthma or eosinophilic inflammation. The study was published in the January 2017 issue of the journal Clinica Chimica Acta.

Related Links:
Abbott Laboratories

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.